Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 11, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR interests for specific individuals following the re-investment of dividends paid on January 5, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the re-investment of dividends at a price of $52.29 per ADR for the following individuals:
- Dr W Calhoun: 35,579 ADRs
- Dr J P Garnier: 249,127 ADRs
- Mr D Phelan: 53,383 ADRs
Investor Verification Checklist
- Verify the dividend payment date of January 5, 2006, and the corresponding re-investment price of $52.29 per ADR.
- Confirm the updated shareholdings of Dr W Calhoun, Dr J P Garnier, and Mr D Phelan in the company's Ordinary Share ADRs.
- Review the GlaxoSmithKline Performance Share Plan rules regarding mandatory re-investment of dividends.